If you are working in computer-aided drug design, this in silico talk is for you: SIB Senior Research Scientist Ute Röhrig takes you on a journey to push the boundaries of knowledge around IDO1 and its role in immunotherapy resistance. IDO1’s promising properties caused an initial ‘gold rush’ from the pharma sector in search of inhibitors. But the effect of IDO1 inhibition proved to be complex in the clinics, and the pharma’s interest faded. The paper Ute and her colleagues recently published in the Journal of Medicinal Chemistry leverages 15 years of research on the mechanism and inhibition of IDO1: in this talk you will learn about the tools and approaches they used, applicable to any other drug target, but also what it takes to prepare for a renaissance of IDO1 as a target in cancer or other pathologies.
Open the video in YouTube to access its description with more information about the speaker, individual chapters, etc.
The “in silico talks” online series aims to provide bioinformaticians, life scientists and clinicians with the latest advances in bioinformatics methods, research and resources led by SIB Scientists, in a wide range of topics. Would you like to stay abreast of the latest developments, get exclusive insights into recent papers, and discover how these advances might help you in your work or research? Read more and subscribe to the mailing list to receive the next talk.
REFERENCE
Röhrig U et al. Structure and Plasticity of Indoleamine 2,3-Dioxygenase 1 (IDO1). J. Med. Chem. 2021, 64, 24, 17690–17705 https://doi.org/10.1021/acs.jmedchem.1c01665